Literature DB >> 16020664

Cancer growth and spread are saltatory and phase-locked to the reproductive cycle through mediators of angiogenesis.

Patricia A Wood1, Kathleen Bove, Shaojin You, Ann Chambers, William J M Hrushesky.   

Abstract

The frequency of breast cancer metastatic spread is affected by the menstrual cycle phase of its resection. Breast cancer growth, post-resection spread, and cure frequency are each modulated by the estrous cycle in C(3)HeB/FeJ mice. Tumor metastases are 2- to 3-fold more frequent when the resection is done during diestrus as compared with estrus. Tumor angiogenesis is essential for both cancer growth and lethal metastatic cancer spread. The balance between vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) modulates new blood vessel formation and blood vessel permeability. Sex hormones modulate the expression of these key angiogenesis regulators in the endometrium and uterus. We, therefore, asked whether the estrous cycle modulates the density of CD31-positive vessels within the tumor, the permeability of tumor blood vessels, levels of VEGF and bFGF immunoreactive protein in normal breast and breast cancer, and whether expression of these genes are modulated by the estrous cycle stage in C(3)HeB/FeJ mice. We find that tumor blood vessel density and blood volume do not vary throughout the cycle; however, tumor capillary permeability is regulated by the estrous cycle being highest in diestrus, the cycle stage associated with the highest cancer growth rate and the highest frequency of post-resection cancer metastasis. VEGF protein levels in breast cancer are >100-fold higher than in normal breast. VEGF protein in this mammary tumor varies with the estrus cycle with highest levels in proestrus. In a non-breast tumor, methylcholantrenene A sarcoma, from CD(2)F(1) mice, tumor VEGF protein also varies with the estrus cycle with highest levels in proestrus and diestrus. VEGF gene expression in the mammary tumor does not change significantly across the cycle, but is modulated by the cycle in normal breast tissue. bFGF protein concentration is 6-fold higher in normal breast than in breast cancer. bFGF protein pattern in both tumor and breast are similar, opposite to VEGF, and affected by oophorectomy. bFGF message is modulated by the cycle in both breast cancer and normal breast. The changes in breast cancer capillary permeability, VEGF, and bFGF that occur during each fertility cycle, in breast tissue and breast cancer, putatively in response to cyclical changes in sex hormones, might contribute, at least in part, to both the modulation of cancer growth and post-resection breast cancer spread by the fertility cycle. These fertility cycle-induced effects on tumor biology also seem to extend to non-breast cancer biology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16020664     DOI: 10.1158/1535-7163.MCT-05-0028

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  13 in total

1.  Broad tissue expression of membrane progesterone receptor Alpha in normal mice.

Authors:  Shaojin You; Lian Zuo; Vijay Varma
Journal:  J Mol Histol       Date:  2010-05-15       Impact factor: 2.611

2.  Ovarian surface epithelium receptors during pregnancy and estrus cycle of rats with emphasis on steroids and gonadotropin fluctuation.

Authors:  Salina Y Saddick
Journal:  Saudi J Biol Sci       Date:  2014-03-13       Impact factor: 4.219

3.  Neurosteroid effects at α4βδ GABAA receptors alter spatial learning and synaptic plasticity in CA1 hippocampus across the estrous cycle of the mouse.

Authors:  Nicole Sabaliauskas; Hui Shen; Jonela Molla; Qi Hua Gong; Aarti Kuver; Chiye Aoki; Sheryl S Smith
Journal:  Brain Res       Date:  2014-12-24       Impact factor: 3.252

4.  17β Hydroxysteroid dehydrogenase type 12 (HSD17B12) is a marker of poor prognosis in ovarian carcinoma.

Authors:  Marta Szajnik; Miroslaw J Szczepanski; Esther Elishaev; Carmen Visus; Diana Lenzner; Maciej Zabel; Marta Glura; Albert B DeLeo; Theresa L Whiteside
Journal:  Gynecol Oncol       Date:  2012-08-17       Impact factor: 5.482

Review 5.  Does iron have a role in breast cancer?

Authors:  Xi Huang
Journal:  Lancet Oncol       Date:  2008-08       Impact factor: 41.316

6.  Optimizing the time of Doxil injection to increase the drug retention in transplanted murine mammary tumors.

Authors:  Shaojin You; Lian Zuo; Wei Li
Journal:  Int J Nanomedicine       Date:  2010-04-07

7.  Estrous cycle modulates ovarian carcinoma growth.

Authors:  Guillermo N Armaiz-Pena; Lingegowda S Mangala; Whitney A Spannuth; Yvonne G Lin; Nicholas B Jennings; Alpa M Nick; Robert R Langley; Rosemarie Schmandt; Susan K Lutgendorf; Steven W Cole; Anil K Sood
Journal:  Clin Cancer Res       Date:  2009-04-21       Impact factor: 12.531

8.  Preclinical development of a neutral, estrogen receptor-targeted, tridentate 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative for imaging of breast and endometrial cancers.

Authors:  Tapan K Nayak; Helen J Hathaway; Chinnasamy Ramesh; Jeffrey B Arterburn; Donghai Dai; Larry A Sklar; Jeffrey P Norenberg; Eric R Prossnitz
Journal:  J Nucl Med       Date:  2008-05-15       Impact factor: 10.057

9.  Progesterone protects normative anxiety-like responding among ovariectomized female mice that conditionally express the HIV-1 regulatory protein, Tat, in the CNS.

Authors:  Jason J Paris; Jason Fenwick; Jay P McLaughlin
Journal:  Horm Behav       Date:  2014-04-12       Impact factor: 3.587

10.  Biological stoichiometry in tumor micro-environments.

Authors:  Irina Kareva
Journal:  PLoS One       Date:  2013-01-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.